NRG Semiannual Meetings

Save the date to join us for the next NRG Oncology Semiannual Meeting July 16-18, 2020. Future meeting dates can be found here

Learn more about our trials

Our protocol table has information and documents pertaining to our currently accruing and past NRG Oncology clinical trials. Search through our protocols here.

Improving the lives of cancer patients

NRG Oncology is making strides to improve the lives of those affected by cancer through practice-changing clinical and translational research. Learn more about who we are and what we do

Search for clinical trials.

Search Publications Search Protocols

A Focus On Science

NRG Oncology and its partners have more than 150 years' experience in conducting practice-defining, multi-institutional phase II and III trials sponsored primarily by the National Cancer Institute (NCI), as well as a history of undertaking the kind of phase I trials and transnational biological studies that will be imperative for future clinical cancer research.

NCI Community Oncology Research Programs

Uniquely positioned

Internationally recognized investigators populate the leadership and membership of all seven cancer disease site committees encompassed by NRG Oncology.

Brain tumors
Breast cancer
Gastrointestinal cancer
Genitourinary cancer
Gynecologic cancer
Head and Neck cancer
Lung cancer

Learn More For Patients

NRG is a platform to find better treatment for cancer of tomorrow.

Patient Story

Clinical trials provide hope for
cancer fighters like me. Laurie

Our Mission

Improve the lives of cancer patients by conducting practice-changing multi-institutional clinical and translational research

Dr. Robert S. Mannel

Our exceptional network brings individuals together who are passionate about changing the future of cancer care through impactful clinical trials.

Membership Resources

NRG Oncology's membership roster is comprised of over 1,000 member sites including institutions on five continents. Our investigators represent all of the oncologic medical specialties and disciplines.

Learn More

Latest News

NRG Oncology trial shows immunotherapy is safe following chemoradiotherapy for women with node-positive cervical cancer

Results from the NRG Oncology phase I clinical trial NRG-GOG 9929 show that utilizing the immunotherapy drug ipilimumab after chemoradiotherapy (CRT) is tolerated in the curative treatment of women with lymph node-positive cervical cancer. The maximum tolerated dose of ipilimumab was determined to be 10 mg/kg.

Breast-conserving treatment without surgery not supported at this time: Results of NRG Oncology study BR005

Results from NRG Oncology's BR005 study show that breast-conserving treatment without surgery cannot be recommended, based on the study criteria of clinical complete response, radiological complete response (rCR)/near rCR, and negative tumor bed biopsies.

NRG Oncology Trial shows that standard of care chemoradiation for Stage III non-small cell lung cancer is superior to two tested alternatives

Lung cancer is the leading cause of cancer death in the United States and approximately 75-80% of all cases are non-small cell lung cancer (NSCLC). Of these, 30-40% are considered locally advanced and are categorized as either Stage IIIA or IIIB.

See All Posts

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.